FDA OKs Crizotinib for Myofibroblastic Tumors
The tyrosine kinase inhibitor has already been approved for certain patients with non-small cell lung cancer and anaplastic large cell lymphoma.
Source: medscape.com
Watch Reporting System News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Watch Reporting System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Watch Reporting System Today - Breaking & Trending Today
FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune...
Source: prnewswire.com
FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune...
Source: prnewswire.com
FDA approves osimertinib as adjuvant therapy for non-small cell lung
On December 18, 2020, the Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Efficacy was demonstrated in a randomized, double-blind, placebo-controlled trial (ADAURA, NCT02511106) in patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC who had complete tumor resection, with or without prior adj...
Source: fda.gov